Literature DB >> 11751147

Antipneumococcal activity of BMS 284756 compared to those of six other agents.

Glenn A Pankuch1, Kensuke Nagai, Todd A Davies, Michael R Jacobs, Peter C Appelbaum.   

Abstract

Antipneumococcal activity of BMS 284756 was compared to those of six agents by MIC and time-kill methodologies. BMS 284756 had the lowest MICs compared to those of ciprofloxacin, levofloxacin, and moxifloxacin against quinolone-susceptible (< or =0.016 to 0.06 microg/ml) and quinolone-resistant (0.03 to 1 microg/ml) pneumococci. BMS 284756 was bactericidal against 11 of 12 strains at two times the MIC after 24 h.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11751147      PMCID： PMC126976          DOI： 10.1128/AAC.46.1.251-254.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  J Liñares; A G de la Campa; R Pallares
Journal:  N Engl J Med       Date:  1999-11-11       Impact factor: 91.245

2.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 3.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

5.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 7.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

8.  Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

9.  Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.

Authors:  S K Spangler; M R Jacobs; G A Pankuch; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1993-02       Impact factor: 5.790

10.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191
View more
  7 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 3.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.

Authors:  María Pérez-Vázquez; Federico Román; Belen Aracil; Rafael Cantón; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

5.  In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.

Authors:  Patrick Grohs; Serge Houssaye; Agnès Aubert; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

7.  Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.

Authors:  K J Christiansen; J M Bell; J D Turnidge; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.